Transition to chronic pain: opportunities for novel therapeutics

Theodore J Price¹, Allan I Basbaum², Jacqueline Bresnahan², Jan F Chambers³, Yves De Koninck⁴, Robert R Edwards⁵, Ru-Rong Ji⁶, Joel Katz⁷, Annemieke Kavelaars⁸, Jon D Levine², Linda Porter⁹, Neil Schechter⁵, Kathleen A Sluka¹⁰, Gregory W Terman¹¹, Tor D Wager¹², Tony L Yaksh¹³, Robert H Dworkin¹⁴

Affiliations

¹ The University of Texas at Dallas, Richardson, TX, USA. Theodore.price@utdallas.edu.
² University of California, San Francisco, San Francisco, CA, USA.
³ National Fibromyalgia and Chronic Pain Association, Logan, UT, USA.
⁴ Laval University & CERVO Brain Research Centre, Québec, QC, Canada.
⁵ Harvard University, Boston, MA, USA.
⁶ Duke University, Durham, NC, USA.
⁷ York University, Toronto, ON, Canada.
⁸ University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁹ National Institutes of Health, Bethesda, MD, USA.
¹⁰ University of Iowa, Iowa City, IA, USA.
¹¹ University of Washington, Seattle, WA, USA.
¹² University of Colorado, Boulder, CO, USA.
¹³ University of California, San Diego, San Diego, CA, USA.
¹⁴ University of Rochester, Rochester, NY, USA.

PMID: 29765159
PMCID: PMC6237656
DOI: 10.1038/s41583-018-0012-5

Transition to chronic pain: opportunities for novel therapeutics

Theodore J Price et al. Nat Rev Neurosci. 2018 Jul.

. 2018 Jul;19(7):383-384.

doi: 10.1038/s41583-018-0012-5.

Authors

Affiliations

¹ The University of Texas at Dallas, Richardson, TX, USA. Theodore.price@utdallas.edu.
² University of California, San Francisco, San Francisco, CA, USA.
³ National Fibromyalgia and Chronic Pain Association, Logan, UT, USA.
⁴ Laval University & CERVO Brain Research Centre, Québec, QC, Canada.
⁵ Harvard University, Boston, MA, USA.
⁶ Duke University, Durham, NC, USA.
⁷ York University, Toronto, ON, Canada.
⁸ University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁹ National Institutes of Health, Bethesda, MD, USA.
¹⁰ University of Iowa, Iowa City, IA, USA.
¹¹ University of Washington, Seattle, WA, USA.
¹² University of Colorado, Boulder, CO, USA.
¹³ University of California, San Diego, San Diego, CA, USA.
¹⁴ University of Rochester, Rochester, NY, USA.

PMID: 29765159
PMCID: PMC6237656
DOI: 10.1038/s41583-018-0012-5

Abstract

Although chronic pain is one of the most important medical problems facing society, there has been very limited progress in the development of novel therapies for this condition. Here, we discuss high-impact research priorities to reduce the number of people transitioning from acute to chronic intractable pain.

PubMed Disclaimer

Conflict of interest statement

Competing interests

The authors declare no competing interests.

References

1. Ji RR, Chamessian A, Zhang YQ. Science. 2016;354:572–577. - PMC - PubMed
1. Apkarian AV, Baliki MN, Farmer MA. Curr Opin Neurol. 2013;26:360–367. - PMC - PubMed
1. Denk F, McMahon SB, Tracey I. Nat Neurosci. 2014;17:192–200. - PubMed
1. Skolnick P, Volkow ND. Neuron. 2016;92:294–297. - PubMed
1. Braz JM, et al. Neuron. 2012;74:663–675. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Transition to chronic pain: opportunities for novel therapeutics

Affiliations

Transition to chronic pain: opportunities for novel therapeutics

Authors

Affiliations

Abstract

Conflict of interest statement

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical